2024-05-05 04:02:32 ET
Summary
- Puma Biotechnology's pipeline is evolving, but analysts express "Hold" sentiments due to its stagnant pipeline over the past few years.
- The company's lone approved product, neratinib, is being marketed for HER2-positive breast cancer, but competition in the HER2 space is fierce.
- Puma Biotechnology's future outlook remains uncertain, with the success of its pipeline projects, particularly alisertib, being highly risky.
...
Read the full article on Seeking Alpha
For further details see:
Puma Biotechnology: A Story In Flux Heading Into Mid-2024